• Product NameAZD5153
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityAZD 5153 an orally available, bivalent inhibitor of the bromodomain and extraterminal (BET) protein BRD4 (IC50?= 5 nM).?It can simultaneously bind two bromodomains in BRD4, which has been shown to increase antitumor activity in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B cell lymphoma.
• Target NameEpigenetic Reader Domain inhibitor
• CAS No. 1869912-40-2
• Calculated MW 667.75
• Formulation C25H33N7O3.C11H8O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CC1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C.C1=CC2=C(C=CC(=C2)O)C=C1C(=O)O
  Pathways:Chromatin/Epigenetic
  Receptor:BD1-BRD4; FL-BRD4
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL (149.75 mM); Ethanol: 27 mg/mL (40.43 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. 1. Rhyasen, G.W.,Hattersley, M.M.,Yao, Y., et al. AZD5153: A novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol. Cancer Ther. 2016, 15(11), 2563-2574.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting